| afatinib |
inhibition of oxygen/glucose-induced neuroinflammation and EGFR
activation |
(56) |
| erlotinib |
reduction
in Aβ-induced memory loss in
AD |
(57) |
| gefitinib |
improvement in
cognition and memory functions |
(57) |
| |
may improve AD pathogenesis by inhibiting the β-secretase activity |
(58) |
| imatinib |
inhibition of Aβ accumulation by the
selective inhibition
of BACE activity |
(59) |
| |
promotes degradation
of Aβ by inducing the activity of Aβ-degrading enzyme neprilysin |
(60) |
| |
inhibition
of brain c-Abl, reduction
in circulating levels of Aβ, shifts APP processing to non-amyloidogenic pathway |
(61) |
| sunitinib |
provides neuroprotection by inhibiting NO
production |
(62) |
| |
inhibition of acetylcholinesterase
activity and attenuation
of cognitive impairments in scopolamine-induced AD mice |
(63) |
| vandetanib |
may inhibit
acetylcholinesterase activity in AD |
(64) |
